Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Therapy for Prostate Cancer Study

BJU International

Volumn 103, Issue 5, 2009, Pages 590-596

  Schröder, Fritz H ^a   Bangma, Chris H ^a   Wolff, Johannes M ^b   Alcaraz, Antonio ^c   Montorsi, Francesco ^e   Mongiat Artus, Pierre ^f   Abrahamsson, Per Anders ^g   McNicholas, Tom A ^h   Castro, Ramiro S ^d   Nandy, Indrani M ⁱ  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CARITAS KRANKENHAUS   (Germany)

^c HOSPITAL CLÍNIC   (Spain)

^d GLAXOSMITHKLINE   (Spain)

^e IRCCS SAN RAFFAELE PISANA   (Italy)

^f SAINT LOUIS HOSPITAL   (France)

^g LUND UNIVERSITY HOSPITAL   (Sweden)

^h LISTER HOSPITAL   (United Kingdom)

ⁱ GLAXOSMITHKLINE   (United States)

Author keywords

5 reductase inhibitor; Dutasteride; Prostate cancer; Radical therapy

Indexed keywords

ANDROGEN; CELECOXIB; DUTASTERIDE; FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; ROSIGLITAZONE; SULINDAC SULFONE;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DECISION MAKING; DIABETES MELLITUS; DIET SUPPLEMENTATION; DRUG EFFECT; DRUG EFFICACY; GYNECOMASTIA; HOT FLUSH; HUMAN; IMPOTENCE; LIBIDO DISORDER; MASTALGIA; METABOLIC SYNDROME X; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; AZASTEROIDS; CHEMOTHERAPY, ADJUVANT; CHOLESTENONE 5 ALPHA-REDUCTASE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 60449116534     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08373.x     Document Type: Article

References (39)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007 18 : 581 92
2. Määttänen L, Auvinen A, Stenman UH et al. European randomized study of prostate cancer screening: first-year results of the Finnish trial. Br J Cancer 1999 79 : 1210 4
3. Sandblom G, Varenhorst E, Löfman O, Rosell J, Carlsson P. Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden. Eur Urol 2004 46 : 717 23
4. Vis AN, Roemeling S, Reedijk AM, Otto SJ, Schröder FH. Overall survival in the intervention arm of a randomized controlled screening trial for prostate cancer compared with a clinically diagnosed cohort. Eur Urol 2008 53 : 91 8
5. Heidenreich A, Aus G, Bolla M et al. EAU Guidelines on Prostate Cancer. Eur Urol 2008 53 : 68 80
6. Trapasso JG, deKernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994 152 : 1821 5
7. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999 281 : 1591 7
8. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 2004 172 : S42 6
9. Freedland SJ, Humphreys EB, Mangold LA et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005 294 : 433 9
10. Freedland SJ, Humphreys EB, Mangold LA et al. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol 2007 25 : 1765 71
11. Moul JW, Wu H, Sun L et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 2004 171 : 1141 7
12. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999 341 : 1781 8
13. Messing EM, Manola J, Yao J et al. Eastern Cooperative Oncology Group study EST 3886. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006 7 : 472 9
14. Loblaw DA, Virgo KS, Nam R et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007 25 : 1596 605
15. Braga-Basaria M, Dobs AS, Muller DC et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006 24 : 3979 83
16. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006 24 : 4448 56
17. Smith MR. Treatment-related osteoporosis in men with prostate cancer. Clin Cancer Res 2006a 12 : 6315s 6319s
18. Stephenson AJ, Shariat SF, Zelefsky MJ et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004 291 : 1325 32
19. Stephenson AJ, Scardino PT, Kattan MW et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007 25 : 2035 41
20. Andriole G, Lieber M, Smith J et al. Treatment with finasteride following radical prostatectomy for prostate cancer. Urology 1995 45 : 491 7
21. Goluboff ET, Prager D, Rukstalis D et al. Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy. J Urol 2001 166 : 882 6
22. Smith MR, Manola J, Kaufman DS et al. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer 2004 101 : 1569 74
23. Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol 2006b 24 : 2723 8
24. Schröder FH, Roobol MJ, Boevé ER et al. Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary. Eur Urol 2005 48 (Suppl. 922 30
25. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab 2004 89 : 2179 84
26. Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res 2006 12 : 4072 9
27. Andriole GL, Humphrey P, Ray P et al. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol 2004 172 : 915 9
28. Iczkowski KA, Qiu J, Qian J et al. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer Volume in human prostate. Urology 2005 65 : 76 82
29. Gleave M, Qian J, Andreou C et al. The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer - results from a 4-month pre-radical prostatectomy study. Prostate 2006 66 : 1674 85
30. Montgomery B, Mostaghel EA, Vessella R et al. Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth. Cancer Res 2008 68 : 4447 54
31. Thomas LN, Douglas RC, Vessey JP et al. 5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium. J Urol 2003 170 : 2019 25
32. Titus MA, Gregory CW, Ford OH Schell MJ, Maygarden SJ, Mohler JL. Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 2005 11 : 4365 71
33. Luo J, Dunn TA, Ewing CM, Walsh PC, Isaacs WB. Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma. Prostate 2003 57 : 134 9
34. Thomas LN, Douglas RC, Lazier CB et al. Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer. J Urol 2008 179 : 147 51
35. Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003 349 : 215 24
36. Scher HI, Eisenberger M, D'Amico AV et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 2004 22 : 537 56
37. Miller K, Steiner U, Lingnau A et al. Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer. ASCO 2007 Annual Meeting. Available at: http://www.asco.org/ASCO/ Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=Abstract-detail- view&confide=47&abstracted=33936
38. Andriole G, Bostwick D, Brawley O et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004b 172 : 1314 7
39. Fleshner N, Gomella LG, Cookson MS et al. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp Clin Trials 2007 28 : 763 9